[The clinico-epidemiological efficacy of thymogen in acute respiratory viral infections in a military collective].
Furgal. S M SM; Degtiarev. A A AA; Seryĭ. S V SV; Khavinson. V Kh VKh
Key Findings
- Intranasal and subcutaneous thymogen lowered the overall morbidity rate from acute respiratory viral infections.
- The severity (gravity) of infections was reduced in participants who received thymogen.
- Duration of illness episodes was shorter in the thymogen‑treated group compared with controls.
Practical Outcomes
- For self‑experimenters, thymogen appears to have prophylactic potential against common viral colds and flu, especially when administered nasally or via injection. However, the study lacks detailed dosing, safety, and long‑term data, so any personal protocol should start with low doses, monitor immune markers, and consider the limited evidence base before widespread use.
Summary
A study in a military training unit found that giving thymogen, a synthetic thymus peptide, either through the nose or under the skin reduced how many people got flu‑like illnesses, made the cases milder, and shortened how long they lasted.
Abstract
This study gathers the results of epidemiological examination in training military unit, making evaluation of prophylactic efficiency of timogen, i.e. synthetic peptide of thymus for flu and other acute respiratory infections (ARI). The high clinico-epidemiological efficiency of timogen was proved in intranasal and subcutaneous administration that had led to a considerable reduction of morbidity rate, gravity and duration of ARI. Experimental substantiation for timogen administration was obtained that proved its efficiency for flu and other ARI prophylaxis in military units.
Study Information
pubmed
1993